Cleared Traditional

K871696 - DOUBLE ANTIBODY AMPHETAMINE KAPD1 AND K...

K871696 is the FDA 510(k) clearance for DOUBLE ANTIBODY AMPHETAMINE KAPD1 AND K... by Diagnostic Products Corp.. It is a Class 2 Toxicology device (product code DKZ) cleared through the Traditional 510(k) pathway after a 36-day FDA review.

K871696 · Diagnostic Products Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1987
Decision
36d
Days
Class 2
Risk

K871696 is an FDA 510(k) clearance for the DOUBLE ANTIBODY AMPHETAMINE KAPD1 AND KAPD5. Classified as Enzyme Immunoassay, Amphetamine (product code DKZ), Class II - Special Controls.

Submitted by Diagnostic Products Corp. (Los Angeles, US). The FDA issued a Cleared decision on June 5, 1987 after a review of 36 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3100 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Diagnostic Products Corp. devices

Submission Details

510(k) Number K871696 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 30, 1987
Decision Date June 05, 1987
Days to Decision 36 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
51d faster than avg
Panel avg: 87d · This submission: 36d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DKZ Enzyme Immunoassay, Amphetamine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DKZ Enzyme Immunoassay, Amphetamine

All 114
Devices cleared under the same product code (DKZ) and FDA review panel - the closest regulatory comparables to K871696.
REVISED LABELING FOR SYVA AMPHETAMINE ASSAY
K874080 · Syva Co. · Oct 1987
LABELING CHANGE AMPHETAMINE DOUBLE ANTIBODY
K873755 · Diagnostic Products Corp. · Oct 1987
ACA DU PONT URINE AMPHETAMINES (U AMP) SCREEN METH
K873622 · E.I. Dupont DE Nemours & Co., Inc. · Oct 1987
TDX AMPHETAMINE METHAMPHETAMINE
K853879 · Abbott Laboratories · Oct 1985
EMIT D.A.U. AMPHETAMINE ASSAY
K842674 · Syva Co. · Sep 1984
EMIT 700 AMPHETAMINE ASSAY NEW PRODUCT
K843458 · Syva Co. · Sep 1984